Literature DB >> 1971539

Systemic effects of three beta-blocker eyedrops: comparison in healthy volunteers of beta 1- and beta 2-adrenoreceptor inhibition.

C Le Jeunne1, Y Munera, F C Hugues.   

Abstract

The beta 1- and beta 2-adrenoreceptor blockade by means of the systemic diffusion of three beta-blocker eyedrops--timolol, carteolol, and betaxolol--was evaluated in a randomized, single-blind, three-way crossover study in 18 volunteers. The blockade was evaluated by analyzing the variations of the beta 1- and beta 2-blockade effects of isoproterenol before and after instillation of one drop in each eye. The beta 1-blockade effect was judged on the variation of heart rate, and the beta 2-blockade effect was judged on the change in peripheral blood flow measured by veno-occlusive plethysmography. Comparison of the blockade by these drops showed that carteolol and timolol totally inhibited the beta 1 and beta 2 effects of a dose of isoproterenol able to increase heart rate by 50% (placebo eyedrops were used as a control). Betaxolol differ significantly because it allowed the same effects with the same dose of isoproterenol. Intensity of the blockade was measured by comparison of the effective doses of isoproterenol. Carteolol and timolol were shown to be four times more inhibitory.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971539     DOI: 10.1038/clpt.1990.78

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

Review 3.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

4.  Influence of betaxolol and timolol on the venous tone in glaucoma patients.

Authors:  L Bojic; J Bagatin; M Ivanisevic; I Hozo; G Racic; D Karelovic
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

5.  Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects.

Authors:  K G Bauer; F Brunner-Ferber; L M Distlerath; E A Lippa; B Binkowitz; P Till; G A Kaik
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 6.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

7.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

Review 8.  Systemic and local tolerability of ophthalmic drug formulations. An update.

Authors:  F C Hugues; C Le Jeunne
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.